CTLA4 and neoplasm: Indeed, we observed a combined anti-tumor effect of E7046 and anti-CTLA-4 antibodies compared with each agent alone in this same 4T1 model accompanied by 12.5% tumor-free mice (Fig. 4F), providing additional evidence that EP4 antagonism combined with a Treg cell reduction treatment is a functional strategy to enhance anti-tumor activity.